I-Mab Biopharma Co., Ltd. (IMAB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of I-Mab Inc. (IMAB)

The price trajectory shown below for I-Mab (IMAB), which has an EV/EBITDA value of , correlates with the recruitment of global experts through generous bonuses and Western management. Following the separation from its Chinese unit, I-Mab is independently developing US research and eschewing mergers. Business resilience relies on the efficacy of oncology drugs, support from venture capital funds, and approvals from US and PRC regulators.

IMAB I-Mab Biopharma: Enterprise Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/10/2026

IMAB (i-mabbiopharma.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes I-Mab Biopharma|IMAB - Fair Value Consensus
- market capitalization indicators:
Market Value I-Mab Biopharma|IMAB - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share I-Mab|IMAB - Accounting Capitalization|Market Capitalization to Book Value Ratio i-mabbiopharma.com|IMAB - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity I-Mab|IMAB - Long-Term Liabilities to Capital|Short-Term Debt to Equity I-Mab Biopharma|IMAB - Company Debts|Debt to Book Capitalization Ratio I-Mab Biopharma|IMAB - Long-Term Debt|Company Short-Term Debts I-Mab|Quick Liquidity Indicator i-mabbiopharma.com
- business earnings and investment ratios data:
IMAB - Company Net Income|Future Profit I-Mab|IMAB - Company Value to Net Income|Projected Price to Earnings I-Mab Biopharma|IMAB - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple I-Mab Biopharma|IMAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) I-Mab|IMAB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months i-mabbiopharma.com|IMAB - Earnings per share increase in current year|Earnings growth forecast for next year I-Mab
Summary company analytics:IMAB (I-Mab Inc.)
Original product of I-Mab Biopharma

Analyzing I-Mab through the historical EV/EBITDA trajectory allows for a comparison of the total enterprise value, including liabilities, against its operational profitability. The current value of reflects the efficiency of generating cash flows before taxes, depreciation, and amortization. This multiple is sensitive to debt load, which is critical when financing antibody development. For a biotech company, this serves as an indicator of the ability to monetize licensing agreements with pharma behemoths.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|FENC (Fennec Pharmaceuticals Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Heron Therapeutics Inc (HRTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuvectis Pharma, Inc. (NVCT)|CHRS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Corbus Pharmaceuticals Holdings CRBP|Cardiff Oncology Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BYSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BioAtla, Inc.|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)